A detailed history of Balanced Rock Investment Advisor transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Balanced Rock Investment Advisor holds 5,953 shares of GILD stock, worth $562,022. This represents 0.39% of its overall portfolio holdings.

Number of Shares
5,953
Previous 5,993 0.67%
Holding current value
$562,022
Previous $411 Million 21.38%
% of portfolio
0.39%
Previous 0.35%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$66.59 - $83.99 $2,663 - $3,359
-40 Reduced 0.67%
5,953 $499 Million
Q2 2024

Jul 31, 2024

SELL
$63.15 - $72.88 $1,831 - $2,113
-29 Reduced 0.48%
5,993 $411 Million
Q1 2024

May 13, 2024

SELL
$71.58 - $87.29 $33,213 - $40,502
-464 Reduced 7.15%
6,022 $441 Million
Q4 2023

Feb 13, 2024

BUY
$73.27 - $83.09 $475,229 - $538,921
6,486 New
6,486 $525 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $118B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Balanced Rock Investment Advisor Portfolio

Follow Balanced Rock Investment Advisor and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balanced Rock Investment Advisor, based on Form 13F filings with the SEC.

News

Stay updated on Balanced Rock Investment Advisor with notifications on news.